345 related articles for article (PubMed ID: 29437595)
21. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
22. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
[TBL] [Abstract][Full Text] [Related]
23. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
24. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
25. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
26. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
Loh ML
Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
[TBL] [Abstract][Full Text] [Related]
28. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
[TBL] [Abstract][Full Text] [Related]
30. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
[TBL] [Abstract][Full Text] [Related]
31. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.
Poetsch AR; Lipka DB; Witte T; Claus R; Nöllke P; Zucknick M; Olk-Batz C; Fluhr S; Dworzak M; De Moerloose B; Starý J; Zecca M; Hasle H; Schmugge M; van den Heuvel-Eibrink MM; Locatelli F; Niemeyer CM; Flotho C; Plass C
Epigenetics; 2014 Sep; 9(9):1252-60. PubMed ID: 25147919
[TBL] [Abstract][Full Text] [Related]
32. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
34. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
36. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
38. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
40. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]